Division of Endocrinology and Metabolism, Ege University, İzmir, Turkey.
Division of Pathology, Ege University, İzmir, Turkey.
Hormones (Athens). 2021 Dec;20(4):813-818. doi: 10.1007/s42000-021-00301-6. Epub 2021 Aug 14.
Pituicytoma is a rare tumor of the pituitary gland derived from neurohypophyseal pituicytes. CASE 1: A 58-year-old female presented with decreased vision; she was admitted to the neurosurgery department of Ege University after the detection of a pituitary macroadenoma. Magnetic resonance imaging (MRI) showed a 28 * 18 * 17-mm suprasellar mass, and laboratory tests revealed hypopituitarism. Hydrocortisone and L-thyroxine treatment were initiated, and the patient underwent resection through the endoscopic endonasal approach (EEA). The histopathological examination revealed a pituicytoma. The recurrence of tumor was detected during the 1-year follow-up, and the patient is awaiting surgery. CASE 2: A 70-year-old woman presented with visual changes; she had a past medical history of hypophyseal macroadenoma and pituicytoma resected through an EEA in 2012 and 2017, respectively. During follow-up, 2 years after the second surgery, MRI showed progression of the pituicytoma then measuring 38 × 23 × 22 mm; it had invaded the cavernous sinus and was causing hydrocephaly and panhypopituitarism. The patient underwent the third resection through the transcranial approach in order to minimize bleeding. After this surgery, the patient developed diabetes insipidus and underwent treatment with desmopressin. Histopathological examination revealed a pituicytoma. At 6-month follow-up, imaging showed a sellar suprasellar mass 37 × 22 × 24 mm invading the cavernous sinus, indicative of recurrence. In the postoperative period, the patient applied to the department of radiation oncology to have fractionated radiotherapy.
Pituicytomas are known to be low-grade tumors; because of their rarity, they are a real challenge. These patients should be followed up closely.
垂体细胞瘤是一种罕见的垂体肿瘤,来源于神经垂体的垂体细胞。
病例 1:一名 58 岁女性因视力下降就诊,在检测到垂体大腺瘤后被收入 Ege 大学神经外科。磁共振成像(MRI)显示鞍上有一个 281817mm 的肿块,实验室检查显示垂体功能减退。开始给予氢可的松和左甲状腺素治疗,患者通过内镜经鼻入路(EEA)进行了切除。组织病理学检查显示为垂体细胞瘤。在 1 年的随访中发现肿瘤复发,患者正在等待手术。
病例 2:一名 70 岁女性因视力变化就诊,她有垂体大腺瘤病史,曾分别于 2012 年和 2017 年通过 EEA 进行了垂体细胞瘤切除术。在随访中,第二次手术后 2 年,MRI 显示垂体细胞瘤进展,大小为 382322mm;它已侵犯海绵窦,并导致脑积水和全垂体功能减退。为了减少出血,患者通过经颅入路进行了第三次切除。手术后,患者出现尿崩症,并接受了去氨加压素治疗。组织病理学检查显示为垂体细胞瘤。在 6 个月的随访中,影像学显示鞍上蝶鞍肿块 372224mm 侵犯海绵窦,提示复发。在术后期间,患者向放射肿瘤科申请接受分次放疗。
垂体细胞瘤是已知的低度恶性肿瘤;由于其罕见性,它们是一个真正的挑战。这些患者应密切随访。